Press release July 15, 2019: Development of a new leishmaniasis drug wins EU funding
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of a Neglected Infectious (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps...
> Read More
Also available in:
Dutch - German - Farsi - French